Journal
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
Volume -, Issue -, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2023.2252496
Keywords
EGFR; lung cancer; benzimidazole-1,2,3-triazole hybrids; pharmacophore modeling; ADME
Categories
Ask authors/readers for more resources
In this study, a library of 1843 benzimidazole-1,2,3-triazole hybrids was screened to identify potential epidermal growth factor receptor (EGFR) inhibitors for lung cancer treatment. The identified compounds showed stable interactions with EGFR and exhibited favorable drug-likeness properties and low toxicity. This research provides important insights into the development of potent and selective EGFR inhibitors for lung cancer treatment.
Lung cancer is a complex and heterogeneous disease, which has been associated with various molecular alterations, including the overexpression and mutations of the epidermal growth factor receptor (EGFR). In this study, designed a library of 1843 benzimidazole-1,2,3-triazole hybrids and carried out pharmacophore-based screening to identify potential EGFR inhibitors. The 164 compounds were further evaluated using molecular docking and molecular dynamics simulations to understand the binding interactions between the compounds and the receptor. In-si-lico ADME and toxicity studies were also conducted to assess the drug-likeness and safety of the identified compounds. The results of this study indicate that benzimidazole-1,2,3-triazole hybrids BENZI-0660, BENZI-0125, BENZI-0279, BENZI0415, BENZI-0437, and BENZI-1110 exhibit dock scores of 9.7, 9.6, 9.6, 9.6, 9.6, 9.6 while referencing molecule 7.9kcal/mol for EGFR (PDB ID: 4HJO), respectively. The molecular docking and molecular dynamics simulations revealed that the identified compounds formed stable interactions with the active site of EGFR, indicating their potential as inhibitors. The in-silico ADME and toxicity studies showed that the compounds had favorable drug-likeness properties and low toxicity, further supporting their potential as therapeutic agents. Finally, performed DFT studies on the best-selected ligands to gain further insights into their electronic properties. The findings of this study provide important insights into the potential of benzimidazole-1,2,3-triazole hybrids as promising EGFR inhibitors for the treatment of lung cancer. This research opens up a new avenue for the discovery and development of potent and selective EGFR inhibitors for the treatment of lung cancer. [GRAPHICS]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available